• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

    5/5/25 4:01:00 PM ET
    $CLDX
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $CLDX alert in real time by email

    HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting the hypothesis that treating EoE with barzolvolimab—a mast cell depleting agent—could provide promising therapeutic benefit. The data were discussed in a poster presentation at the Digestive Disease Week (DDW) 2025 conference in San Diego today. Celldex announced in February 2025 that enrollment to the Phase 2 study is complete and that clinical results are expected in the second half of 2025.

    "These data continue to add to a growing body of literature suggesting that eosinophilic esophagitis involves more than just eosinophils and that mast cells play an important role in the disease process," said Evan S. Dellon, MD, MPH, Professor of Medicine and Director of the Center for Esophageal Diseases and Swallowing at the University of North Carolina School of Medicine and the lead author of the poster. "This is further supported by previous findings that mast cells are present in the biopsy tissue of some patients who continue to suffer from EoE even after eosinophils have been depleted. Barzolvolimab has been shown to deplete cutaneous mast cells and we believe it will likely also deplete esophageal mast cells, which could lead to clinical improvement in EoE—an indication that sorely needs additional effective treatment options. I look forward to seeing the clinical data from the study later this year."

    EoE is the most common type of eosinophilic gastrointestinal disease, a chronic inflammatory disease of the esophagus characterized by the infiltration of eosinophils. Chronic inflammation can result in trouble swallowing, chest pain, vomiting and impaction of food in the esophagus – a medical emergency. Several studies have suggested that mast cells may be an important driver in the disease. Mast cells are present and activated in the esophageal epithelium of EoE biopsy specimens1-11, are important sources of inflammatory cytokines2,9 and are associated with disease features of EoE including histological abnormalities and pain5,7,12,13,14. Mast cells persist in patients who are refractory to topical corticosteroid therapy, even when eosinophils regress13. The Phase 2 "EvolvE" study is designed to test the hypothesis that barzolvolimab, a monoclonal antibody (mAb) against c-KIT previously shown to deplete cutaneous mast cells15, will deplete esophageal mast cells and lead to clinical improvement in EoE.

    Phase 2 EvolvE presentation details: "Intraepithelial Mast Cells are Elevated in Active Eosinophilic Esophagitis and Correlate with Eosinophils: Baseline Data from a Randomized Controlled Trial of Barzolvolimab"; poster #Mo1345

    • Ongoing 28-week, randomized, double-blind, placebo controlled study evaluating 300 mg of barzolvolimab or placebo administered every 4 weeks in participants with known EoE. Eligible participants have at least 15 eosinophils per high power field (hpf) in 2 of 3 segments of the esophagus and at least 4 dysphagia days in the 2 weeks prior to baseline (dysphagia symptom questionnaire [DSQ] score ≥ 8). Primary endpoint is reduction in peak esophageal epithelial mast cell count (PMC) cell at 12 weeks, with key secondary endpoints of reduction in peak eosinophil count (PEC) and reduction in DSQ at 12 weeks.



    • Pinch biopsies from 151 screened participants were obtained at screening from three different esophageal segments (proximal, middle, distal). Screening histology data from this trial demonstrate that high numbers of intraepithelial mast cells are present in participants with active EoE and correlate with eosinophil counts:



      • Intraepithelial mast cells (Tryptase and CD117 positive) and eosinophil counts per hpf from screening biopsies were enumerated by IHC and H&E staining. Similar numbers of cells were observed across the three biopsy sites, with a trend towards greater numbers in the distal esophagus. Participants who failed screening due to low eosinophil counts also tended to have lower tryptase+ and CD117+ mast cell counts.



      • Pearson correlations show a strong association between both CD117+ or tryptase+ total and peak mast cells and eosinophils, as well as between CD117+ and tryptase+ total and peak mast cells.
    • Patients are currently completing treatment and the follow up phase on study; clinical data from the study is expected to be presented in the second half of 2025.

    References: 1Tappata et al. Allergy 2018; 2Aceves et al. JACI 2010; 3Abonia et al. JACI 2010; 4Colombo et al. WJGPT 2013; 5Dellon et al. AJG 2011; 6Lomazi et al. Arq Gast 2017; 7Zhang et al. JACI 2024; 8Kleuskens et al. Muc Imm 2023; 9Ben-Baruch Morgenstern et al. JACI 2022; 10Dunn et al. JACI 2020; 11Kirsch et al. JPGN 2007;12Alvarado et al. Allergy 2023;13Bolton et al. AMJ 2020; 14Zhang et al. Allergy 2022;15Terhorst-Molawi et al. Allergy 2023.

    About Eosinophilic Esophagitis (EOE):

    EoE, the most common type of eosinophilic gastrointestinal disease, is a chronic inflammatory disease of the esophagus characterized by the infiltration of eosinophils. This chronic inflammation can result in trouble swallowing, chest pain, vomiting and impaction of food in the esophagus – a medical emergency. Currently, there are limited treatment options for EoE. Several studies have suggested that mast cells may be an important driver in the disease. Given the lack of effective therapies for EoE and barzolvolimab's potential as a mast cell depleting agent, Celldex believes EoE is an important indication for study. For additional information on the Phase 2 EvolvE study of barzolvolimab in EOE (NCT05774184), please visit clinicaltrials.gov.

    About Barzolvolimab

    Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future.

    About Celldex Therapeutics, Inc.

    Celldex is a clinical stage biotechnology company leading the science at the intersection of mast cell biology and the development of transformative therapeutics for patients. Our pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Visit www.celldex.com.

    Forward Looking Statement

    This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.

    All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.

    Company Contact

    Sarah Cavanaugh

    Senior Vice President, Corporate Affairs & Administration

    (508) 864-8337

    [email protected]

    Patrick Till

    Meru Advisors

    (484) 788-8560

    [email protected]



    Primary Logo

    Get the next $CLDX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLDX

    DatePrice TargetRatingAnalyst
    4/28/2025$64.00Buy
    Canaccord Genuity
    3/20/2025$46.00Overweight
    Morgan Stanley
    2/13/2025$44.00Buy
    UBS
    10/7/2024$70.00Buy
    Citigroup
    9/30/2024$45.00Neutral
    Goldman
    9/27/2024Outperform → Peer Perform
    Wolfe Research
    6/18/2024$58.00Buy
    Stifel
    6/11/2024$51.00Outperform
    Wolfe Research
    More analyst ratings

    $CLDX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Marino James J gifted 10,500 shares, decreasing direct ownership by 83% to 2,204 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/20/24 4:02:46 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/12/24 8:01:10 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SVP AND CFO Martin Samuel Bates exercised 20,169 shares at a strike of $10.16 and sold $608,315 worth of shares (17,172 units at $35.42), increasing direct ownership by 12% to 28,125 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      6/18/24 4:05:20 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • PRESIDENT & CEO Marucci Anthony S bought $308,430 worth of shares (11,500 units at $26.82), increasing direct ownership by 40% to 40,284 units (SEC Form 4)

      4 - Celldex Therapeutics, Inc. (0000744218) (Issuer)

      11/12/24 8:01:10 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Celldex Reports First Quarter 2025 Financial Results and Provides Corporate Update

      Strong execution and progress across pipeline with multiple key data read outs expected in 2025Late breaking oral presentation on Phase 2 CSU program at EAACI 2025 in JunePhase 3 barzolvolimab CSU studies enrollment ongoing; Phase 3 program in CIndU under developmentPhase 2 EOE study enrollment complete; ongoing enrollment in Phase 2 PN and AD studiesCelldex's first bispecific for inflammatory diseases, CDX-622, Phase 1 study ongoing HAMPTON, N.J., May 08, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2025 and provided a corporate update. "In the first quarter of 2025, we presented data from our Ph

      5/8/25 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease

      HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company's ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence of high numbers of intraepithelial mast cells in participants with active EoE and correlate with eosinophil counts, supporting the hypothesis that treating EoE with barzolvolimab—a mast cell depleting agent—could provide promising therapeutic benefit. The data were discussed in a poster presentation at the Digestive Disease Week (DDW) 2025 conference in San Diego today. Celldex announced in February 2025 that enrollment to the Phase 2 st

      5/5/25 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics to Present at Upcoming Investor Conferences

      HAMPTON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that management will participate in fireside chats at two upcoming conferences: TD Cowen 45th Annual Health Care Conference on Tuesday, March 4th at 1:50 p.m. ET Leerink Partners Global Healthcare Conference on Tuesday, March 11th at 1:00 p.m. ET Live webcasts of the presentations will be available on the "Events & Presentations" page of the "Investors & Media" section of the Celldex website. Replays will be available for 90 days following the event. About Celldex Therapeutics, Inc.Celldex is a clinical stage biotechnology company leading the science at the intersection of mast ce

      3/4/25 8:01:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Financials

    Live finance-specific insights

    See more

    $CLDX
    Leadership Updates

    Live Leadership Updates

    See more
    • Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

      First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 developmentCompany to host webcast call Monday at 8:00 am ET HAMPTON, N.J., Oct. 26, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive results from the Company's Phase 2 clinical trial of barzolvolimab in two of the most common forms of chronic inducible urticaria (CIndU)—cold urticaria (ColdU) and symptomatic dermographism (SD). The study includes patients who remain symptomatic despite treatment with antihistamines. Barzolvolimab is a humaniz

      10/26/24 5:43:20 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Presents Landmark 52 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EADV 2024

      - 71% of patients (150 mg Q4W) achieved complete response at Week 52 -- Rapid, profound and durable improvement in UAS7 as early as Week 1 with a deepening of response over 52 weeks -- Robust improvement across omalizumab-experienced/refractory/naïve disease -- Well tolerated through 52 weeks -- Enrollment to Global Phase 3 CSU trials underway -- Company to host webcast today at 12:00 pm ET/6:00 pm CEST - HAMPTON, N.J., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today new data demonstrating sustained and deepening disease efficacy and a well tolerated safety profile over a 52 week treatment period for barzolvolimab in chronic spontaneous

      9/25/24 10:45:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria

      - Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups -- Sustained activity with rapid onset within 2 weeks -- Similar improvement in omalizumab-experienced/refractory and omalizumab-naïve disease consistent with unique mechanism of action -- Favorable safety profile -- 52 week results and Phase 3 CSU trial initiations anticipated in 2024 -- Company to host webcast February 25th at 9:45 am ET- HAMPTON, N.J., Feb. 24, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today positive 12 week results from the Company's Phase 2 clinical trial of barzolvolim

      2/24/24 2:05:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

      HAMPTON, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) announced today that it has appointed Rita Jain, M.D. to the Company's Board of Directors. "We are pleased to welcome Dr. Jain to the Celldex Board of Directors at this important time in the Company's trajectory," said Anthony Marucci, Co-founder, President and Chief Executive Officer of Celldex Therapeutics. "Dr. Jain's deep background in drug development strongly complements our Board's skills and experiences, and we look forward to her contributions as we continue to advance our programs into later stage development." Dr. Jain added, "I am excited to join Celldex, whose emerging data suggests tha

      2/16/23 4:01:00 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosion, Inc. Appoints Joel Edwards, MBA, as Chief Business Officer

      NEWARK, Del. and NANJING, China, Feb. 21, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Joel Edwards as chief business officer. In this position, he is responsible for strategic leadership over all aspects of the company's global business development and alliance management activities. He will report to Dr. Mingjiu Chen, chief executive officer (CEO). Prior to joining Biosion, Mr. Edwards was most recently vice president of corporate strategy and operations at Ionis Pharmaceuticals. "We are delighted to welcome Joel to our executive leadership team in this important role as we continue to expand global busin

      2/21/22 12:00:00 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biosion, Inc. Appoints Anthony Yeh, Ph.D., as Chief Strategy Officer and Head of China BD

      NEWARK, Del. and NANJING, China, Jan. 3, 2022 /PRNewswire/ -- Biosion, Inc. ("Biosion"), a global clinical stage biotechnology company, today announced the appointment of Dr. Anthony Yeh to the position of Chief Strategy Officer and Head of China business development (BD), where he will lead corporate strategy, China BD, and capital fundraising. He will report to Dr. Mingjiu Chen, Chief Executive Officer (CEO). Prior to joining Biosion, Dr. Yeh was most recently Vice President, Head of Corporate Strategy, Investor Relations and Capital Market at CStone Pharmaceuticals (HKSE:2616). "We are pleased to welcome Anthony to Biosion as we continue to expand globally and strengthen our executive le

      1/3/22 5:00:00 AM ET
      $ABT
      $CLDX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $CLDX
    SEC Filings

    See more
    • SEC Form 10-Q filed by Celldex Therapeutics Inc.

      10-Q - Celldex Therapeutics, Inc. (0000744218) (Filer)

      5/8/25 4:06:23 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Celldex Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Celldex Therapeutics, Inc. (0000744218) (Filer)

      5/8/25 4:01:36 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form DEF 14A filed by Celldex Therapeutics Inc.

      DEF 14A - Celldex Therapeutics, Inc. (0000744218) (Filer)

      4/21/25 8:01:28 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 7:47:25 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 12:18:08 PM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Celldex Therapeutics Inc.

      SC 13G/A - Celldex Therapeutics, Inc. (0000744218) (Subject)

      11/14/24 6:12:56 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $CLDX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Canaccord Genuity initiated coverage on Celldex Therapeutics with a new price target

      Canaccord Genuity initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $64.00

      4/28/25 8:36:51 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Morgan Stanley initiated coverage on Celldex Therapeutics with a new price target

      Morgan Stanley initiated coverage of Celldex Therapeutics with a rating of Overweight and set a new price target of $46.00

      3/20/25 7:59:39 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • UBS initiated coverage on Celldex Therapeutics with a new price target

      UBS initiated coverage of Celldex Therapeutics with a rating of Buy and set a new price target of $44.00

      2/13/25 8:07:26 AM ET
      $CLDX
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care